A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)
Key facts
- Who runs it
- Takeda
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 30 Jan 2024
- Ended
- 30 Dec 2024
- Type of study
- Observational, 2 groups
- Record updated
- 23 October 2023
- Why it stopped
- Business reason, unrelated to product safety
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Cohort 1 and 2:
- Participants with a diagnosis of locally advanced or metastatic NSCLC, clinical staging of IIIB-IV; Cohort-1:
- Participants who have received NGS testing and have EGFR ex20ins positive result; Cohort-2:
- Participants who have received NGS testing
Who cannot take part
- Incomplete information, including key demographic characteristics, clinicopathological characteristics, and genetic testing information
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main aim of this study is to examine the percentage of people with lung cancer who carry a certain gene mutation (epidermal growth factor receptor exon 20 insertions - EGFR ex20ins) and their frequency in Chinese participants with Non-small cell lung cancer (NSCLC) after having been tested for the gene mutation.
Read full original descriptionShow less
Data from the participant's electronic medical records at the hospital will be collected.
The 2 groups in the trial
- Cohort 1: Participants With Positive EGFR ex20ins Detection
Participants with NSCLC having positive EGFR ex20ins detected by NGS were observed retrospectively for three years prior to leading site initiation.
- Cohort 2: Participants With Positive and Negative EGFR ex20ins Detection
Participants with NSCLC having positive and negative EGFR ex20ins NGS testing results were observed retrospectively for three years prior to leading site initiation.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- To Investigate EGFR Exon20 Insertion Mutation Testing Methodologies, Clinicopathological Characteristics and Molecular Epidemiology in Chinese Patients With Advanced NSCLC: a Nationwide Multicentre Real-world Registry Study
- Record updated
- 23 October 2023